Background: A key feature of the inflammatory response after cerebral ischemia is the brain infiltration of blood monocytes. There are two main monocyte subsets in the mouse blood: CCR2Ly6C "inflammatory" monocytes involved in acute inflammation, and CX3CR1Ly6C "patrolling" monocytes, which may play a role in repair processes. We hypothesized that CCR2Ly6C inflammatory monocytes are recruited in the early phase after ischemia and transdifferentiate into CX3CR1Ly6C "repair" macrophages in the brain.

Methods: CX3CR1CCR2 bone marrow (BM) chimeric mice underwent transient middle cerebral artery occlusion (MCAo). Mice were sacrificed from 1 to 28 days later to phenotype and map subsets of infiltrating monocytes/macrophages (Mo/MΦ) in the brain over time. Flow cytometry analysis 3 and 14 days after MCAo in CCR2 mice, which exhibit deficient monocyte recruitment after inflammation, and NR4A1 BM chimeric mice, which lack circulating CX3CR1Ly6C monocytes, was also performed.

Results: Brain mapping of CX3CR1 and CCR2 cells 3 days after MCAo showed absence of CX3CR1 Mo/MΦ but accumulation of CCR2 Mo/MΦ throughout the ischemic territory. On the other hand, CX3CR1 cells accumulated 14 days after MCAo at the border of the infarct core where CCR2 accrued. Whereas the amoeboid morphology of CCR2 Mo/MΦ remained unchanged over time, CX3CR1 cells exhibited three distinct phenotypes: amoeboid cells with retracted processes, ramified cells, and perivascular elongated cells. CX3CR1 cells were positive for the Mo/MΦ marker Iba1 and phenotypically distinct from endothelial cells, smooth muscle cells, pericytes, neurons, astrocytes, or oligodendrocytes. Because accumulation of CX3CR1Ly6C Mo/MΦ was absent in the brains of CCR2 deficient mice, which exhibit deficiency in CCR2Ly6C Mo/MΦ recruitment, but not in NR4A1 chimeric mice, which lack of circulating CX3CR1Ly6C monocytes, our data suggest a local transition of CCR2Ly6C Mo/MΦ into CX3CR1Ly6C Mo/MΦ phenotype.

Conclusions: CX3CR1Ly6C arise in the brain parenchyma from CCR2Ly6C Mo/MΦ rather than being de novo recruited from the blood. These findings provide new insights into the trafficking and phenotypic diversity of monocyte subtypes in the post-ischemic brain.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5097435PMC
http://dx.doi.org/10.1186/s12974-016-0750-0DOI Listing

Publication Analysis

Top Keywords

chimeric mice
12
cx3cr1 cells
12
ccr2ly6c mo/mΦ
12
mo/mΦ
10
cells
9
phenotypic diversity
8
post-ischemic brain
8
14 days mcao
8
mice exhibit
8
nr4a1 chimeric
8

Similar Publications

We previously developed human CAR macrophages (CAR-M) and demonstrated redirection of macrophage anti-tumor function leading to tumor control in immunodeficient xenograft models. Here, we develop clinically relevant fully immunocompetent syngeneic models to evaluate the potential for CAR-M to remodel the tumor microenvironment (TME), induce T cell anti-tumor immunity, and sensitize solid tumors to PD1/PDL1 checkpoint inhibition. In vivo, anti-HER2 CAR-M significantly reduce tumor burden, prolong survival, remodel the TME, increase intratumoral T cell and natural killer (NK) cell infiltration, and induce antigen spreading.

View Article and Find Full Text PDF

Background: Several approaches are being explored for engineering off-the-shelf chimeric antigen receptor (CAR) T cells. In this study, we engineered chimeric Fcγ receptor (FcγR) T cells and tested their potential as a versatile platform for universal T cell therapy.

Methods: Chimeric FcγR (CFR) constructs were generated using three distinct forms of FcγR, namely CD16A, CD32A, and CD64.

View Article and Find Full Text PDF

Chimeric antigen receptor with novel intracellular modules improves antitumor performance of T cells.

Signal Transduct Target Ther

January 2025

State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Department of Biochemistry and Molecular Biology, Fourth Military Medical University, Xi'an, Shaanxi, China.

The excessive cytokine release and limited persistence represent major challenges for chimeric antigen receptor T (CAR-T) cell therapy in diverse tumors. Conventional CARs employ an intracellular domain (ICD) from the ζ subunit of CD3 as a signaling module, and it is largely unknown how alternative CD3 chains potentially contribute to CAR design. Here, we obtained a series of CAR-T cells against HER2 and mesothelin using a domain comprising a single immunoreceptor tyrosine-based activation motif from different CD3 subunits as the ICD of CARs.

View Article and Find Full Text PDF

Tumor development often requires cellular adaptation to a unique, high metabolic state; however, the molecular mechanisms that drive such metabolic changes in TFE3-rearranged renal cell carcinoma (TFE3-RCC) remain poorly understood. TFE3-RCC, a rare subtype of RCC, is defined by the formation of chimeric proteins involving the transcription factor TFE3. In this study, we analyzed cell lines and genetically engineered mice, demonstrating that the expression of the chimeric protein PRCC-TFE3 induced a hypoxia-related signature by transcriptionally upregulating HIF1α and HIF2α.

View Article and Find Full Text PDF

ETV7 limits the antiviral and antitumor efficacy of CD8 T cells by diverting their fate toward exhaustion.

Nat Cancer

January 2025

State Key Laboratory of Molecular Oncology, School of Life Sciences, Tsinghua-Peking Center for Life Sciences, Tsinghua University, Beijing, China.

Terminal exhaustion is a critical barrier to antitumor immunity. By integrating and analyzing single-cell RNA-sequencing and single-cell assay for transposase-accessible chromatin with sequencing data, we found that ETS variant 7 (ETV7) is indispensable for determining CD8 T cell fate in tumors. ETV7 introduction drives T cell differentiation from memory to terminal exhaustion, limiting antiviral and antitumor efficacy in male mice.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!